IVIG+IVMP is developed by Chinese PLA General Hospital.

What development phase is IVIG+IVMP in?

IVIG+IVMP is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

IVIG+IVMP

Chinese PLA General Hospital · FDA-approved active Small molecule Quality 6/100

At a glance

Generic name	IVIG+IVMP
Sponsor	Chinese PLA General Hospital
Modality	Small molecule
Therapeutic area	Immunology
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study (PHASE4)
CPI Combination Therapy for Autoimmune Encephalitis (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

IVIG+IVMP CI brief — competitive landscape report
IVIG+IVMP updates RSS · CI watch RSS
Chinese PLA General Hospital portfolio CI